We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Detects Chronic Traumatic Encephalopathy During Life

By LabMedica International staff writers
Posted on 22 Mar 2016
Image: The NanoSight LM10 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
Image: The NanoSight LM10 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
Chronic traumatic encephalopathy (CTE) is a tauopathy associated with prior exposure to repetitive head impacts, such as those incurred through American football and other collision sports and diagnosis is made through neuropathological examination.

A method has been developed for measuring plasma exosomal tau. Exosomes are very small vesicles that are released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood.

Scientists at Boston University School of Medicine (MA, USA) and their colleagues examined 78 former National Football League (NFL) players and a control group of 17 former non-contact sport athletes. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Blood was drawn by venipuncture and immediately processed. Plasma samples were stored in 0.75 mL tubes at -80 °C, packed in dry ice, and shipped overnight in one batch to the Exosome Sciences laboratory (Monmouth Junction, NJ, USA).

Extracellular vesicles were isolated from the plasma samples by size exclusion chromatography. Plasma samples were applied to the column and it was then run isocratically. The elution was monitored at 280 nm and the void volume material (exosome fraction) was collected and pooled. The size profiles and concentrations of the chromatographically isolated exosomes were performed using the Nanosight LM10 instrument (Malvern Instruments Ltd.; Malvern, UK) equipped with a 405 nm laser, a scientific complementary metal-oxide-semiconductor (sCMOS) camera and Nanoparticle Tracking Analysis (NTA) software.

The method of measuring plasma exosomal tau is referred to as a TauSome. The groups did not differ in total plasma exosomes, but the NFL group had significantly higher plasma exosomal tau than the control group. The C-statistic is maximized when the plasma exosomal tau level is set to 0. Using 0 as a threshold resulted in 82% sensitivity, 100% specificity, 100% positive predictive value and 53% negative predictive value. The number of tau-positive plasma exosomes was significantly correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance.

Jim Joyce, Founder of Exosome Sciences and Chairman and CEO of Aethlon Medical (San Diego, CA, USA), said, “We are extremely pleased that our initial study data has been published and we appreciate forthcoming opportunities to further advance our TauSome biomarker as a noninvasive solution to detect and monitor CTE in living individuals.” The study was published on February 10, 2016, in the Journal of Alzheimer's Disease.

Related Links:

Boston University School of Medicine
Exosome Sciences
Malvern Instruments Ltd.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.

Channels

Molecular Diagnostics

view channel
Image: Dr. Maria “Ken” Figueroa is investigating how epigenetics can inform treatment paths for cancer patients. (Image Credit: Sylvester Comprehensive Cancer Center)

DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce healthy blood cells normally. Treatment selection can be challenging because clinicians cannot reliably predict which... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Melioidosis is a serious, sometimes fatal infection caused by Burkholderia pseudomallei, a bacterium found in tropical and subtropical soil and surface water. (Image Credit: Adobe Stock)

Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions

Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more